Phase III aducanumab trials for Alzheimer's disease stopped early
Pharmaceutical companies Biogen and Eisai today (Thursday 21 March) announced they are to discontinue two phase III trials of the Alzheimer's drug aducanumab. The ENGAGE and EMERGE trials were designed to evaluate the efficacy ...
Mar 22, 2019
0
5